In Vitro Antiviral Activity of Two Host Defense Peptides Against Human alphaherpesvirus 1
Abstract Viral infections are continually emerging with new characteristics and the potential to cause outbreaks or pandemics. Therefore, identification of new antiviral compounds is extremely necessary for therapeutic. This study aimed to evaluate the in vitro action of host defense peptides against Human alphaherpesvirus 1 (HHV-1) replication. Vero cell monolayers were infected with HHV-1 $ TCID_{50} $ and treated with different concentrations of IDR-1018 and DJK-6. The cell viability was evaluated by MTT method. Time of addition assays were performed to infer the effect of peptides upon the viral replicative cycle. IDR-1018 and DJK-6 were able to inhibit the HHV-1 replication in maximum nontoxic concentrations. However, IDR-1018 presented higher potency and a better safety profile. In addition, IDR-1018 probably inhibits adhesion, entry and post entry of virus infection. DJK-6 seems to be capable of interfering with virus entry and viral biosynthesis..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
International journal of peptide research and therapeutics - 30(2024), 3 vom: 18. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rodrigues, Gisele Regina [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature B.V. 2024 |
|---|
| doi: |
10.1007/s10989-024-10597-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR05519110X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR05519110X | ||
| 003 | DE-627 | ||
| 005 | 20240319064653.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240319s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10989-024-10597-8 |2 doi | |
| 035 | |a (DE-627)SPR05519110X | ||
| 035 | |a (SPR)s10989-024-10597-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.76 |2 bkl | ||
| 100 | 1 | |a Rodrigues, Gisele Regina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In Vitro Antiviral Activity of Two Host Defense Peptides Against Human alphaherpesvirus 1 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature B.V. 2024 | ||
| 520 | |a Abstract Viral infections are continually emerging with new characteristics and the potential to cause outbreaks or pandemics. Therefore, identification of new antiviral compounds is extremely necessary for therapeutic. This study aimed to evaluate the in vitro action of host defense peptides against Human alphaherpesvirus 1 (HHV-1) replication. Vero cell monolayers were infected with HHV-1 $ TCID_{50} $ and treated with different concentrations of IDR-1018 and DJK-6. The cell viability was evaluated by MTT method. Time of addition assays were performed to infer the effect of peptides upon the viral replicative cycle. IDR-1018 and DJK-6 were able to inhibit the HHV-1 replication in maximum nontoxic concentrations. However, IDR-1018 presented higher potency and a better safety profile. In addition, IDR-1018 probably inhibits adhesion, entry and post entry of virus infection. DJK-6 seems to be capable of interfering with virus entry and viral biosynthesis. | ||
| 650 | 4 | |a Viral infections |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antiviral |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Host defense peptides |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Berlanda, Rhayfa Lorrayne Araujo |4 aut | |
| 700 | 1 | |a Vilas Boas, Liana Costa Pereira |4 aut | |
| 700 | 1 | |a de Lima, Lídia Maria Pinto |4 aut | |
| 700 | 1 | |a Franco, Octávio Luiz |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of peptide research and therapeutics |d Springer Netherlands, 2005 |g 30(2024), 3 vom: 18. März |h Online-Ressource |w (DE-627)SPR05509161X |w (DE-600)2192632-3 |w (DE-576)254902375 |x 1573-3904 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:3 |g day:18 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10989-024-10597-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.76 |j Aminosäuren |j Peptide |j Eiweiße |x Biochemie |q VZ |
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 3 |b 18 |c 03 | ||